| Q36059474 | A case of motor neuron disease presenting as dyspnea in the emergency department |
| Q33850895 | A high-throughput screen to identify inhibitors of SOD1 transcription. |
| Q33616544 | A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma |
| Q49907440 | A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma |
| Q34104378 | A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? |
| Q38741121 | Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis |
| Q90617289 | Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis |
| Q36428039 | Ageing and neuronal vulnerability |
| Q28075617 | Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma |
| Q34459374 | Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis |
| Q35697831 | Assessment and management of treatment-refractory obsessive-compulsive disorder in children |
| Q80551928 | Carcinoma of the tongue and bulbar-onset amyotrophic lateral sclerosis: unusual differential diagnosis |
| Q30599549 | Chemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development |
| Q24613511 | Clinical and experimental applications of sodium phenylbutyrate |
| Q33910597 | Complex genetics of amyotrophic lateral sclerosis |
| Q92186536 | Cu/Zn-superoxide dismutase and wild-type like fALS SOD1 mutants produce cytotoxic quantities of H2O2 via cysteine-dependent redox short-circuit |
| Q47868914 | Current Advances and Limitations in Modeling ALS/FTD in a Dish Using Induced Pluripotent Stem Cells |
| Q47738138 | Cysteine to Serine Conversion at 111th Position Renders the Disaggregation and Retains the Stabilization of Detrimental SOD1 A4V Mutant Against Amyotrophic Lateral Sclerosis in Human-A Discrete Molecular Dynamics Study |
| Q36968254 | Delayed post-injury administration of riluzole is neuroprotective in a preclinical rodent model of cervical spinal cord injury |
| Q38730523 | Endothelial and Astrocytic Support by Human Bone Marrow Stem Cell Grafts into Symptomatic ALS Mice towards Blood-Spinal Cord Barrier Repair |
| Q51801549 | Evaluation of sham non-invasive ventilation for randomized, controlled trials in ALS. |
| Q38681744 | Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer |
| Q33578284 | Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model |
| Q47837504 | Fingerprint analysis of Huolingshengji Formula and its neuroprotective effects in SOD1G93A mouse model of amyotrophic lateral sclerosis |
| Q35806256 | Humoral factors in ALS patients during disease progression. |
| Q33745558 | Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis |
| Q26765787 | Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases |
| Q91646512 | Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer |
| Q35122078 | Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer |
| Q37431333 | Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer |
| Q37502074 | Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer |
| Q57292785 | Motor Neuron Abnormalities Correlate with Impaired Movement in Zebrafish that Express Mutant Superoxide Dismutase 1 |
| Q37039466 | Motor neuron disease and frontotemporal lobar degeneration: a tale of two disorders linked to TDP-43. |
| Q42155772 | Mouse models of Huntington disease: variations on a theme. |
| Q37589114 | NADPH oxidase in brain injury and neurodegenerative disorders |
| Q36283426 | Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration. |
| Q35113722 | Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo |
| Q26742196 | Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis |
| Q36615226 | Plasma and cerebrospinal fluid-based protein biomarkers for motor neuron disease |
| Q47829271 | Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis. |
| Q38881707 | Potential new complication in drug therapy development for amyotrophic lateral sclerosis |
| Q38432879 | Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility |
| Q24629266 | Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder |
| Q42697702 | Riluzole Serum Concentration in Pediatric Patients Treated for Obsessive-Compulsive Disorder. |
| Q36475830 | Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression |
| Q53624330 | Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma. |
| Q89608062 | Riluzole: a therapeutic strategy in Alzheimer's disease by targeting the WNT/β-catenin pathway |
| Q36835575 | Role of zinc in ALS. |
| Q36396423 | Rosmarinic Acid Alleviates Neurological Symptoms in the G93A-SOD1 Transgenic Mouse Model of Amyotrophic Lateral Sclerosis |
| Q34234969 | Screening for inhibitors of the SOD1 gene promoter: pyrimethamine does not reduce SOD1 levels in cell and animal models |
| Q36775620 | Structural Dynamics of Human Argonaute2 and Its Interaction with siRNAs Designed to Target Mutant tdp43. |
| Q34285497 | Targeting NOX enzymes in the central nervous system: therapeutic opportunities. |
| Q37731451 | The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells |
| Q51090549 | The proteinopathy of D169G and K263E mutants at the RNA Recognition Motif (RRM) domain of tar DNA-binding protein (tdp43) causing neurological disorders: A computational study. |
| Q93014731 | Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review |
| Q36543516 | Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. |
| Q42664780 | Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice |
| Q34117516 | Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis |